Navigation Links
PDL BioPharma Provides First Quarter 2011 Revenue Guidance of $83 Million
Date:3/7/2011

crease over the approximately 48,800 patients who were on therapy at the end of December 2009 and that cumulatively 78,800 patients have been treated with Tysabri in the post-marketing setting.  Tysabri royalties are determined at a flat rate as a percent of sales regardless of location of manufacture or sale.

The sales information presented above is based on information provided by PDL's licensees in their quarterly reports to the Company as well as from public disclosures made by PDL's licensees.

About PDL BioPharma PDL pioneered the humanization of monoclonal antibodies and, by doing so, enabled the discovery of a new generation of targeted treatments for cancer and immunologic diseases. PDL is focused on maximizing the value of its antibody humanization patents and related assets. The Company receives royalties on sales of a number of humanized antibody products marketed by leading pharmaceutical and biotechnology companies today based on patents which expire in late 2014. For more information, please visit www.pdl.com.

NOTE: PDL BioPharma and the PDL BioPharma logo are considered trademarks of PDL BioPharma, Inc.

Forward-looking Statements This press release contains forward-looking statements. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Factors that may cause differences between current expectations and actual results include, but are not limited to, the following:

  • The expected rate of growth in royalty-bearing product sales by PDL's existing licensees;
  • The relative mix of royalty-bearing Genentech products manufactured and sold outside the U.S. versus made or sold in the U.S.;
  • The ability of our licensees to receive regulatory approvals to market and launch new royalty-bearing products and whether such products, if launched, wil
    '/>"/>

  • SOURCE PDL BioPharma, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
    2. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
    3. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
    4. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
    5. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
    6. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
    7. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
    8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
    9. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
    10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
    11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2014)... -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a digital pathology ... and education markets, announced today that has been no ... disclosed or, to its knowledge, any other reason to ... "We have noticed unusual price and volume increases for ... Steve Barbee , CEO of DigiPath. "While we ...
    (Date:7/30/2014)...  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: LLTP), a ... expertise in opioid antagonists, announced today that it ... international research and development foundation. The ... initiatives, including those addressing health issues. Lightlake has ... of naloxone that could widely expand its availability ...
    (Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
    Breaking Medicine Technology:DigiPath No New Corporate Developments 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 2Lightlake Therapeutics Inc. Receives Funding Commitment From A Prominent International Research And Development Foundation 3Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2
    ... WASHINGTON, Nov. 1 Multiple myeloma is one,of the ... U.S., but,survival rates have risen dramatically over the past ... to new types of drugs,and aggressive therapeutic interventions such ... studies prepublished online in Blood, the,official journal of the ...
    ... IRVINE, Calif., Nov. 1 IDM Pharma, Inc.,(Nasdaq: ... data,from the Phase 3 mifamurtide (L-MTP-PE) clinical trial (INT-0133). ... funded cooperative,group study conducted by the Children,s Oncology Group ... of patients originally treated in the Phase,3 trial. The ...
    Cached Medicine Technology:Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 2Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 3Studies Attribute Recent Increase in Multiple Myeloma Survival to Novel Therapies 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 2IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 3IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 4IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 5IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients 6
    (Date:7/31/2014)... Parsippany, NJ (PRWEB) July 31, 2014 A ... millions of people survive cancer and resume normal lives. This ... American Cancer Society, will affect one in seven American men ... are, has a five-year survival rate of nearly 100% and ... serious illness but most men diagnosed with the disease do ...
    (Date:7/31/2014)... USHIO America’s Solid State Lighting ... lighting marketplaces, today announced the launch of its ... users to transform existing, inefficient lamp-based downlights to ... USHIO America’s Uphoria LED downlight retrofit kits fit ... the user to upgrade old incandescent recessed lighting ...
    (Date:7/31/2014)... 2014 When guests shop CVS, they’ll find ... to Shea Moisture. And now CVS is adding another acclaimed ... August 1, guests will find G Natural products in CVS ... investment, CEO Roger Gore was inspired to start G’Natural Herbal ... and developing a receding hairline; he tried many products on ...
    (Date:7/30/2014)... Calling all runners in the Richmond, VA region. , Tidewater ... monthly Runner’s Injury Clinic at the Glen Allen ... Monday of each month through the end of the year ... December 8. , The clinics run from 5:30 to ... and attire, will receive a complimentary evaluation of running injuries ...
    (Date:7/30/2014)... (PRWEB) July 31, 2014 WalkingSticksandCane.com ... Walking Canes. The ladies will love the new European fashions ... Sticks . These sticks and canes are from one from ... England. Each of the styles re unique and offer the ... , The Blackthorn Walking Sticks are some of the rarest ...
    Breaking Medicine News(10 mins):Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 2Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 3Health News:Restoring Intimacy after Prostate Cancer; Dr. Daniel Watter with Morris Psychological Group Offers Tips for Patients and their Partners 4Health News:USHIO America Introduces Uphoria™ LED Downlight Retrofit Kits 2Health News:CVS Caremark Adds New, Natural Acclaimed Hair Care Line to its Beauty Roster 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 2Health News:Tidewater Physical Therapy to Host Monthly Runner’s Injury Clinic at 3 Sports Glen Allen Location 3Health News:European Walking Sticks from WalkingSticksandCane.com 2
    ... may be sharply divided in their views on many aspects ... in strong agreement when it comes to one of the ... According to results of the American College of Surgeons (ACS) ... support the establishment of a nationwide trauma system - including ...
    ... Most pregnant women consuming a typical,western diet obtain too ... which is critical for fetal and infant brain,development. This ... panel of nutrition experts summarized in the September 2007,Fats ... called,for pregnant and lactating women to consume at least ...
    ... a Top ... Priority at Newton-Wellesley, RESTON, Va. and ... announced Newton-Wellesley,s use of,the Isabel decision support system to aid ... the implementation,kicks off an initiative to affirm the quality of ...
    ... MESA, Ariz., Oct. 3 The Well Life Center ... and healthcare,education, announces the launch of its "10 Healing ... Donations benefit The Arizona,Special Olympics. This session will ... using the 10 universal laws. Discover how to set ...
    ... Prism Pharmaceuticals,Inc., a privately-held, specialty pharmaceutical company committed ... the appointment of Maurits W. Geerlings, MD, MBA, ... "I am pleased to welcome Dr. Geerlings to ... brings a tremendous amount of relevant,industry experience and ...
    ... Recently, a man, traveling on,business to Scranton, ... by,ambulance to Moses Taylor Hospital where clinicians identified ... recent seizure, the patient was unable to,communicate his ... registration, a form automatically printed out in the ...
    Cached Medicine News:Health News:A nation divided over health care? Not so fast 2Health News:Brain, Eye and Heart Health: Three Reasons to Eat More Omega-3s 2Health News:Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System 2Health News:Newton-Wellesley Hospital First in Massachusetts to Implement Isabel Diagnosis Decision Support System 3Health News:Moses Taylor Hospital Automates Medication Reconciliation 2
    Semi-Automated Chemistry Analyzer with model screen master. The Screen Master incorporates many powerful features in one compact unit. Useful for biochemical investigations, enzymatic, immunoturbidi...
    ... Geometric Data Hemastainer. Formulated to ... quality control tested on human ... staining and absence of precipitate. ... a minimum of eight hours ...
    ... Unique molecular suspension in methanol for ... chromosome, and histology smears. Our special ... rapidly penetrates cellular elements producing unequaled ... detail and unexcelled brilliance in the ...
    Wright-Giemsa Stain Solutions...
    Medicine Products: